Inhibrx Biosciences (INBX) Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Payables data on file, last reported at $5.9 million in Q4 2025.

• On a quarterly basis, Payables fell 35.71% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $5.9 million, a 35.71% decrease from a year earlier, with the FY2025 full-year figure at $5.9 million, down 35.71% from the prior year.
• Payables for Q4 2025 stood at $5.9 million, down from $6.8 million in the prior quarter.
• Over the last five years, Payables for INBX reached as high as $13.0 million in Q2 2024 and fell as low as $5.9 million in Q4 2025.
• Historically, Payables has averaged $9.4 million across 3 years, with a median of $9.1 million in 2024.
• Across the five-year window, Payables decreased 15.6% in 2024 and sank 45.25% in 2025, its largest moves.
• Year by year, Payables stood at $11.0 million in 2023, then dropped by 15.6% to $9.2 million in 2024, then slumped by 35.71% to $5.9 million in 2025.
• Per Business Quant data, the three most recent Payables figures were $5.9 million in Q4 2025, $6.8 million in Q3 2025, and $8.3 million in Q2 2025.